Continuous-rate infusion thrombolysis in acute feline aortic thromboembolism
The goal of this trial, “Continuous-rate infusion thrombolysis with tissue plasminogen activator, pentoxifylline, and cyproheptadine in acute feline aortic thromboembolism (ALPEXC trial),” is to investigate a treatment protocol to optimize clot dissolution in acute aortic thromboembolism in cats (“saddle thrombus”) using a constant infusion of a clot buster (tissue plasminogen activator [TPA or alteplase]) and mitigate side effects of treatment such as acute kidney injury and reperfusion injury.
The study pays for all treatments and monitoring done specifically for the study, an approximately $1,500 value.
- Diagnosis of feline aortic thromboembolism (FATE) with at least 2 limbs affected
- Known onset of acute FATE within the past 3.5 hours
- Cardiogenic FATE (LA:Ao>1.6)
- Ability to start the study drug within 1 hour of presentation to the clinic
Enrollment ends February 28, 2024
If interested in enrolling, please contact the main hospital line at (970) 297-5000 to discuss eligibility with the emergency/urgent care or critical care clinician on duty. As timing is important, you may call the hospital while the cat is already on its way to the Veterinary Teaching Hospital.
Main Hospital Line: (970) 297-5000